Chemotherapy has improved the prognosis of patients with sarcomas. However, it may suppress anti-tumor immunity. Recently, we reported a novel CD8 + memory T cell population with a chemo-resistance property, "young memory" T (T YM ) cells. In this study, we investigated the proportion and function of T YM cells in peripheral blood of healthy donors and sarcoma patients who received chemotherapy and those who did not. The proportion of T YM cells was significantly decreased in patients compared with that in healthy donors. In healthy donors, anti-EBV CTLs were induced using mixed lymphocyte peptide culture, from not only T YM cells but also T CM and T EM cells. No CTLs directed to tumorassociated antigens were induced. In sarcoma patients who did not receive chemotherapy, in addition to anti-EBV CTLs, CTLs directed to the tumor-associated antigen PBF were induced from T YM , T CM and T EM cells. In sarcoma patients who received chemotherapy, EBV-specific CTLs were induced from T YM cells but were hardly induced from T EM cells. Interestingly, CTLs directed to the antitumor-associated antigen PBF were induced from T YM cells but not from the T CM and T EM cells in sarcoma patients who received chemotherapy. The findings suggest that T YM cells are resistant to chemotherapy and can firstly recover from the nadir. T YM cells might be important for immunological memory, especially in sarcoma patients receiving chemotherapy.
B
one and soft tissue sarcomas, especially osteosarcoma, are highly malignant neoplasms and that occurred in children and young adults. The introduction of high-dose chemotherapy has increased the 5-year overall survival of patients with osteosarcoma from 10% up to 70%. (1) However, the prognosis of non-responders to chemotherapy is still poor and new therapeutic modalities are required. We have focused on the development of immunotherapy for sarcoma. We have searched for tumor-associated antigens and CTL epitopes in the context of HLA class I, and we have performed clinical peptide vaccination for patients with osteosarcoma and synovial sarcoma targeting PBF and SYT-SSX, respectively. Immune responses were elicited in many patients, but the responses were generally weak and the objective responses were poor. Some patients showed the clinical responses, and the characteristics of those patients were that: (i) the target lesion was small (≤2 cm); and (ii) they did not receive chemotherapy. (2) These characteristics suggest that chemotherapy can kill sarcoma cells but simultaneously weakens immune surveillance and that intensive chemotherapy has poor compatibility with immunotherapy.
Recently, the existence of chemo-resistant memory T cells, now called memory T stem cells, has been reported. (3, 4) At first, all T cells in neonatal infants are naive. After exposure to various pathogens, the naive T cells (T N ) differentiated into central memory (T CM ), effector memory (T EM ) and effector (T EFF ) T cells in the context of expression of CD45RA, CD45RO, CD62L and CCR7. (5) In the lineage of T cell differentiation, stem cell memory T cells (T SCM ), defined by CD95 + , exist between T N and T CM , and have the characteristics of chemo-resistance, long-living and differentiation into other memory T cell subsets. Recently, Murata et al. (6) reported a novel stem-like memory T cell population, "young memory . T YM cells memorized virus antigens and some tumor-associated antigens in healthy donors and cancer patients, respectively. However, the alteration in the proportion of and the role of T YM cells in sarcoma patients before and after chemotherapy is still unclear.
The purpose of this study was to investigate the proportions of T YM cells and other CD8 + T-cell subsets in healthy donors and in sarcoma patients who received or did not receive chemotherapy. We also assessed the immunological memory directed to viral antigens and tumor-associated antigens in T YM cells and other T cell subsets in sarcoma patients by in vitro stimulation with CTL epitopes in the context of HLA-A24.
Materials and Methods
The present study was performed in accordance with the guidelines established by the Declaration of Helsinki and was approved by the Ethics Committee of Sapporo Medical University. The patients, their families, and healthy donors provided informed consent for the use of blood samples in our research.
Study participants. We obtained peripheral blood mononuclear cells (PBMCs) from 27 sarcoma patients at Sapporo Medical University, Japan. Six patients had osteosarcoma, four had chondrosarcoma, three had MPNST, three had undifferentiated pleomorphic sarcoma, three had leiomyosarcoma, two had parosteal osteosarcoma, two had myxofibrosarcoma, and one patients each had periosteal osteosarcoma, synovial sarcoma, Ewing sarcoma and epithelioid sarcoma. PBMCs were also obtained from of 23 healthy donors.
Antibodies, flow cytometry and cell sorting. Peripheral blood mononuclear cells were stained and separated into T cell subsets as previously described. (6) Briefly, PBMCs were washed twice in PBS and labeled with the following fluorescent antibodies: APC-H7-conjugated anti-CD3, FITC-conjugated anti-CD8, PE-Cy7-conjugated anti-CD45RA, APC-conjugated anti-CD62L, BV421-conjugated anti-CD73, PE-conjugated anti-CXCR3 and PerCP-Cy5.5-conjugated anti-CD95 (BD Biosciences, San Diego, CA, USA; 
CD45RA
À CD62L À cells as T EM cells were sorted. Collected data were analyzed with BD FACSDiva V6.1.3 (BD Bioscience) and GraphPad Prism software version 7 (MDF, Tokyo, Japan). The gating strategy is depicted in Figure S1 .
Mixed lymphocyte peptide culture for antigen-specific CTL induction. Peripheral blood mononuclear cells obtained from HLA-A*24:02 + sarcoma patients and healthy donors sorted into CD8 + T-cell subsets as described above were used as responder cells. The other CD8
À T cells were used as stimulator cells. CD8
À cells (1-2 9 10 5 /well) were incubated for 90 min at room temperature with peptide mix at the concentration of 10 lg/mL. The peptides PBF A24.2 (AYRPVSRNI), (7) survivin2B (AYACNTSTL), (8) HIV env gp160 (RYLRDQQLL) and Epstein-Barr virus (EBV) BRLF1 (TYPVLEEMF) were mixed and pulsed. After incubation, responder cells (0.5-1 9 10 5 well) and stimulator cells (1-2 9 10 5 /well) were co-cultured in 96-microwell plates in 300 lL of AIM-V (Life Technologies Japan Ltd., Tokyo, Japan) with 10% human serum (HS), IL-2 (20 IU/mL; a kind gift from Takeda Chemical Industries, Ltd., Osaka Japan), and IL-7 (10 ng/mL; R&D Systems, Minneapolis, MN, USA). Half of the medium was replaced every 3-4 days with fresh AIM-V containing IL-2 and IL-7. On day 21, the cells were subjected to tetramer-based frequency analysis.
Tetramer-based CTL analysis. The proportion of peptide-specific CTLs was determined by tetramer staining. The HLA-A24/ peptide tetramers were constructed by Medical & Biological Laboratories Co. Ltd. (Nagoya, Japan). Cells were collected from each microwell and centrifuged then incubated with 50 nM of dasatinib (LC Laboratories, Woburn, MA, USA) for 30 min at 37°C. Subsequently, each tetramer was added and incubated for 30 min at room temperature. Then FITC-conjugated anti-CD8 antibody (Clone T8; Beckman Coulter, Brea, CA, USA) was added and incubated for another 20 min. The cells were washed in PBS and analyzed by flow cytometry using a FACS Caliber (Becton Dickinson, San Jose, CA, USA) and CellQuest software (Becton Dickinson). Living cells were gated and the proportions of tetramer-positive cells were calculated as the number of tetramer-positive cells/number of CD8 + cells.
Statistical analysis. GraphPad Prism software version 7 was used for statistical analysis. Student's t-test was used to determine statistical differences. A value of P < 0.05 was considered statistically significant.
Results
The proportion of T YM cells was decreased in sarcoma patients.
At first, we investigated the proportions of CD8 + T cell subsets consisting of T N , T YM , T SCM , T CM and T EM cells in 23 healthy donors and 27 sarcoma patients (Tables 1 and 2 ). The proportion of T N cells in sarcoma patients (mean proportion, 7.2%) was lower than that in healthy donors (24.2%; Fig. 1a ). The proportion of T YM cells in sarcoma patients (mean proportion, 9.0%) was also lower than that in healthy donors (17.08%; P < 0.01). The proportion of T YM cells in sarcoma patients excluding young and elderly patients was also similarly low ( Fig. S2 ). However, there were no significant differences between sarcoma patients and healthy donors in the proportions of T SCM cells (P = 0.67), T CM cells (P = 0.31) and T EM cells (P = 0.09). To investigate the effect of chemotherapy, we compared the proportions of T cell subsets in sarcoma patients who underwent chemotherapy and those who did not undergo. There was no significant difference between the proportion of T YM or T SCM cells, which have drug-resistance capacity, and the proportions of other T cell subsets (Fig. 1b) . Interestingly, only the memory proportion of T YM cells was decreased in sarcoma patients but not in healthy donors. In addition, the proportions of T YM cells were similar in sarcoma patients who received chemotherapy and those who did not. These findings suggest that the initiation of sarcoma might be due to the weakness of immune surveillance by T YM cells and that chemotherapy does not impact the proportions of peripheral T cell subsets including T YM cells. (Fig. 2a,b) . In contrast, tumor-associated antigen-specific CTLs could not be induced from any of the T cell subsets.
T YM cells of sarcoma patients who did not receive chemotherapy memorized both virus-derived antigens and tumor-associated antigens. Next, we performed MLPC using each of the T cell subsets of HLA-A24+ sarcoma patients who did not receive chemotherapy. Anti-EBV-specific CTLs were also induced from T YM cells in 4 of 7 sarcoma patients, from T CM cells in 3 of 7 sarcoma patients and from T EM cells in 5 of 7 sarcoma patients who did not receive chemotherapy (Table 3 , Fig. 2c,  d) . In contrast to healthy donors, CTLs directed to PBF were induced from T YM cells in 3 of 7 sarcoma patients, from T CM cells in 4 of 7 sarcoma patients and from T EM cells in 3 of 7 of sarcoma patients who did not receive chemotherapy. Antisurvivin-2B-specific CTLs were also induced from T CM cells Finally, to investigate the effect of chemotherapy on memory T cell subsets, we performed MLPC using each of the T cell subsets of HLA-A24+ sarcoma patients who received chemotherapy. Despite chemotherapy, EBV-specific CTLs were induced from the memory T cell subsets including T YM cells in 2 of 5 sarcoma patients and T CM cells in 1 of 5 of sarcoma patients who received chemotherapy but were not induced from T EM cells (Table 3 , Fig. 2e) . In Patient 22, anti-EBV-specific CTLs were induced from T YM cells but not from T CM or T EM cells (Fig. 2f) . These results suggested the importance of T YM cells in recovery from the nadir and differentiation of memory subsets after chemotherapy. Regarding tumor-associated antigens, CTLs directed to PBF were induced from T YM cells in 2 of 5 sarcoma patients but not from T CM or T EM cells in sarcoma patients who received chemotherapy. CTLs directed to survivin were induced from T YM cells in 2 of 5 sarcoma patients from T CM cells in 1 of 5 sarcoma patients but not and from T EM cells in sarcoma patients who received chemotherapy (Table 3 , Fig. 2f ). Interestingly, in Patients 20 and 22, anti-PBF-specific CTLs were induced from T YM cells but not from T CM or T EM cells (Fig. 2f) . In Patient 22, anti-survivin-specific CTLs were induced from T YM cells but not from T CM or T EM cells. These results support the idea that T YM cells are resistant to chemotherapy and are firstly recovered to reconstitute the T cell memory subsets after the nadir condition. In contrast to T YM cells, the function of T EM cells was easily impaired by chemotherapy. TYM  TCM  TEM  TYM  TCM  TEM  TYM  TCM  TEM  TYM  TCM 
Discussion
In this study, we demonstrated that: (i) T YM cells existed in PBMCs of both healthy donors and sarcoma patients; (ii) the proportion of T YM cells in sarcoma patients was lower than that in healthy donors; (iii) there was no difference in the proportion of any of the memory T cell subsets between patients who received chemotherapy and those who did not receive chemotherapy; (iv) viral antigen-specific CTL were induced from T YM cells not only in healthy donors but also in sarcoma patients; and (v) tumor-associated antigens PBF and survivinspecific CTLs were induced from T YM cells of sarcoma patients. It is notable that tumor-associated antigen-specific CTLs were weakly induced from T CM cells and not from T EM cells in sarcoma patients who received chemotherapy. These results suggested that T YM cells were important for the maintenance of antigen-specific memory function to protect against pathogens and cancer cells not only in healthy donors but also in sarcoma patients, especially after chemotherapy. The importance of memory T stem cells in self-renewal, long-lasting memory, proliferation and drug resistance has been widely recognized. T SCM cells are useful for generating long-living T cells expressing TCR directed to tumor-associated antigens for adoptive cell transfer therapy. (9, 10) The usefulness of peptide vaccination therapy targeting T SCM cells has not been reported, and we consider that a vaccination strategy to enhance the immunological memory of T SCM cells might be important.
In the present study, we focused on T YM cells as a subset of memory T stem cells. T YM cells express aldehyde dehydrogenase 1 (ALDH1) for drug resistance and are defined by naive markers (CD73   +   CD45RA   +   CD62L + CCR7 + ) and one memory marker (CXCR3 + ) but lacking CD95. Expression status of surface markers suggested that T YM cells might be located closer than T SCM cells to naive cells in the T cell lineage and might be more important for the maintenance and reconstitution of T cell memory. A functional comparison of T YM cells and T SCM cells is essential. However, the proportion of T SCM cells is much lower than T YM cells in peripheral blood and they are difficult to isolate for functional analysis.
We observed that the peripheral proportion of T YM cells in sarcoma patients was lower than that in healthy donors. In contrast to T YM cells, the proportions of T SCM cells were receive chemotherapy (data not shown). Since we successfully obtained CTL clones directed to each epitope in previous studies, immunogenicity of these antigens is promising. Clinical peptide vaccination trials are required to evaluate the immunogenicity directed to CSC/CIC antigens in T YM cells and other T cell subsets.
In conclusion, T YM cells existed and play an important role in anti-virus immune function in sarcoma patients and healthy donors. Moreover, T YM cells have memory directed to tumorassociated antigens in patients with sarcoma who received chemotherapy and those who did not. Finally, the characteristics of T YM cells might be useful for peptide vaccination and adaptive cell transfer in the future.
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